|     Univariate survival analysis |     Multivariate survival analysis | ||
---|---|---|---|---|
 |      Cancer-specific survival |      Cancer-specific survival | ||
 |    Hazard ratio | P-value |    Hazard ratio | P-value |
 |     (95% CI) |  |     (95% CI) |  |
Age (<50/>50Â years) | 1.82 (0.77-4.33) | 0.173 | Â | Â |
Size (≤20/21-50/>50 mm) | 2.04 (1.20-3.49) | 0.009 |  | 0.116 |
Grade (I/II/III) | 1.71 (1.09-2.68) | 0.019 | Â | 0.342 |
Involved lymph node (0/1-3/>3) | 2.26 (1.54-3.32) | <0.001 | 2.11 (1.40-3.20) | <0.001 |
Progesterone -receptor status (PR-/PR+) | 0.72 (0.38-1.37) | 0.316 | Â | Â |
HER-2 status (HER-2 -/HER-2+) | 2.17 (0.96-4.88) | 0.062 | Â | 0.109 |
Ki-67 status (Low Ki-67/High Ki-67) | 3.71 (1.98-6.96) | <0.001 | 3.62 (1.88-7.00) | <0.001 |
LVI (Absent/Present) | 2.98 (1.62-5.47) | <0.001 | 2.36 (1.22-4.58) | 0.011 |
MVD (CD34+) (tertiles 1, 2, 3) | 1.41 (0.95-2.08) | 0.087 | Â | 0.667 |
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) | 1.75 (0.90-3.43) | 0.100 |  |  |
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) | 1.45 (1.03-2.05) | 0.033 |  | 0.481 |